ATE494287T1 - Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase - Google Patents

Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase

Info

Publication number
ATE494287T1
ATE494287T1 AT05722809T AT05722809T ATE494287T1 AT E494287 T1 ATE494287 T1 AT E494287T1 AT 05722809 T AT05722809 T AT 05722809T AT 05722809 T AT05722809 T AT 05722809T AT E494287 T1 ATE494287 T1 AT E494287T1
Authority
AT
Austria
Prior art keywords
pyrazolopyrimidene
cyclin
derivatives
kinase inhibitors
dependent kinase
Prior art date
Application number
AT05722809T
Other languages
German (de)
English (en)
Inventor
Timothy J Guzi
Kamil Paruch
Michael P Dwyer
Ronald J Doll
Viyyoor Moopil Girijavallabhan
Alan Mallams
Carmen S Alvarez
Kartik M Keertikar
Jocelyn Rivera
Tin-Yau Chan
Vincent Madison
Thierry O Fischmann
Lawrence W Dillard
Vinh D Tran
Zhen Min He
Ray Anthony James
Haengsoon Park
Vidyadhar M Paradkar
Douglas Walsh Hobbs
Original Assignee
Schering Corp
Pharmacopeia Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34860861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE494287(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp, Pharmacopeia Llc filed Critical Schering Corp
Application granted granted Critical
Publication of ATE494287T1 publication Critical patent/ATE494287T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05722809T 2004-02-11 2005-02-08 Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase ATE494287T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/776,988 US7119200B2 (en) 2002-09-04 2004-02-11 Pyrazolopyrimidines as cyclin dependent kinase inhibitors
PCT/US2005/003859 WO2005077954A2 (en) 2004-02-11 2005-02-08 Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE494287T1 true ATE494287T1 (de) 2011-01-15

Family

ID=34860861

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05722809T ATE494287T1 (de) 2004-02-11 2005-02-08 Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase

Country Status (26)

Country Link
US (2) US7119200B2 (enExample)
EP (1) EP1720882B1 (enExample)
JP (2) JP4845743B2 (enExample)
KR (1) KR101196498B1 (enExample)
CN (1) CN1946725B (enExample)
AR (1) AR047543A1 (enExample)
AT (1) ATE494287T1 (enExample)
AU (1) AU2005212409C1 (enExample)
BR (1) BRPI0507644B8 (enExample)
CA (1) CA2555345C (enExample)
CY (1) CY1112400T1 (enExample)
DE (1) DE602005025733D1 (enExample)
DK (1) DK1720882T3 (enExample)
ES (1) ES2359410T3 (enExample)
HR (1) HRP20110245T1 (enExample)
IL (1) IL177283A (enExample)
MY (1) MY149044A (enExample)
NO (1) NO337520B1 (enExample)
NZ (1) NZ590480A (enExample)
PE (1) PE20050774A1 (enExample)
PL (1) PL1720882T3 (enExample)
RU (1) RU2414472C9 (enExample)
SI (1) SI1720882T1 (enExample)
TW (1) TWI393566B (enExample)
WO (1) WO2005077954A2 (enExample)
ZA (1) ZA200606573B (enExample)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196092B2 (en) * 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
BRPI0407834A (pt) * 2003-02-28 2006-02-14 Teijin Pharma Ltd composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
GB0321475D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
WO2005035516A1 (ja) * 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. 新規縮合複素環化合物およびその用途
JP2007536369A (ja) * 2004-05-06 2007-12-13 ファイザー・インク プロリン及びモルホリン誘導体の新規化合物
US20080287405A1 (en) * 2004-05-14 2008-11-20 Thannickal Victor J Compositions and Methods Relating to Protein Kinase Inhibitors
RU2006146985A (ru) * 2004-05-28 2008-07-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
AR051966A1 (es) * 2004-11-23 2007-02-21 Astrazeneca Ab Derivados de acido fenoxiacetico utiles para el tratamiento de enfermedades respiratorias
US7850960B2 (en) * 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
CN101193865A (zh) 2005-06-09 2008-06-04 先灵公司 3-氨基-4-取代吡唑衍生物的合成
JP2009502801A (ja) * 2005-07-22 2009-01-29 サネシス ファーマシューティカルズ， インコーポレイテッド Ａｕｒｏｒａキナーゼインヒビターとして有用なピラゾロピリミジン
EP1922321A1 (en) * 2005-08-09 2008-05-21 Eirx Therapeutics Ltd Pyrazoloý1,5-a¨pyrimidine compounds and pharmaceutical compositions containing them
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2635760C (en) * 2005-12-28 2014-07-15 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
BRPI0708693A2 (pt) * 2006-03-08 2011-06-14 Novartis Ag uso de derivados de pirazol[1,5,a]pirimidin-7-il amina no tratamento de distérbios neurolàgicos
AU2007268083A1 (en) * 2006-05-22 2007-12-06 Schering Corporation Pyrazolo [1, 5-A] pyrimidines as CDK inhibitors
EP2405270B1 (en) 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
US7786306B2 (en) * 2006-08-18 2010-08-31 Schering Corporation Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo[1,5-a] pyrimidine derivatives using same
EP2051963B1 (en) * 2006-08-18 2012-05-16 Schering Corporation Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo [1,5-a]pyrimidine derivatives using same
ES2685837T3 (es) * 2006-08-28 2018-10-11 Merck Sharp & Dohme Corp. Proceso y productos intermedios para la síntesis de derivados de (3-alquil-5-piperidin-1-il-3,3a-dihidropirazolo[1,5-a]pirimidin-7-il)-amino
CN101627041A (zh) * 2006-08-28 2010-01-13 先灵公司 合成(3-烷基-5-哌啶-1-基-3,3a-二氢-吡唑并[1,5-a]嘧啶-7-基)-氨基衍生物和中间体的方法和中间体
WO2008140724A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
AU2008261027A1 (en) * 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
WO2009020140A1 (ja) * 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. アダマンチルウレア誘導体
WO2009023160A2 (en) * 2007-08-11 2009-02-19 The Uab Research Foundation Novel inhibitors of bacterial sortase enzymes and methods of using the same
ES2589122T3 (es) * 2007-08-31 2016-11-10 Whitehead Institute For Biomedical Research Estimulación de la ruta de la Wnt en la reprogramación de células somáticas
AU2008301925A1 (en) * 2007-09-17 2009-03-26 Merck Sharp & Dohme Corp. Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
US20100286038A1 (en) * 2007-09-21 2010-11-11 Valentyn Antochshuk Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
EP2212432A4 (en) * 2007-10-22 2011-10-19 Schering Corp COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
CA2722347A1 (en) * 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
AU2009259853A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
EP2296475A4 (en) 2008-06-20 2014-03-05 Genentech Inc TRIAZOLOPYRIDINE COMPOUNDS JAK KINASE INHIBITORS AND METHODS
SG196855A1 (en) 2008-10-22 2014-02-13 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
US8507673B2 (en) * 2008-12-11 2013-08-13 Emory University Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds
WO2010068838A2 (en) * 2008-12-11 2010-06-17 Emory University PROCESSES FOR PREPARING 5,7 DIAMINOPYRAZOLO[1,5-α] PYRIMIDINE COMPOUNDS
EP2417138B1 (en) 2009-04-09 2019-11-27 Merck Sharp & Dohme Corp. Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
EP2421956A4 (en) * 2009-04-24 2013-10-02 Whitehead Biomedical Inst COMPOSITIONS AND METHODS FOR OBTAINING OR CULTURING PLURIPOTENTER CELLS
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
EP2552917B1 (en) * 2010-03-26 2014-11-05 Merck Sharp & Dohme Corp. Process for synthesizing 6-bromo-3-(1-methyl-1h-pyrazol-4-yl)-5-(3(r)-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-amine
AU2011256380C1 (en) 2010-05-20 2016-09-08 Array Biopharma Inc. Macrocyclic compounds as Trk kinase inhibitors
US8957077B2 (en) 2010-09-30 2015-02-17 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE 10 inhibitors
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
ES2913633T3 (es) 2011-09-30 2022-06-03 Bluebird Bio Inc Compuestos para transducción viral mejorada
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP2634189A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
WO2013148775A1 (en) 2012-03-30 2013-10-03 Merck Sharp & Dohme Corp. Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9573954B2 (en) 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
PT2925757T (pt) 2012-11-19 2018-01-09 Novartis Ag Compostos e composições para o tratamento de doenças parasitárias
PL3808749T3 (pl) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
JP2016512239A (ja) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
EP3035964B1 (en) 2013-08-20 2020-09-23 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
PL3077397T3 (pl) 2013-12-06 2020-04-30 Vertex Pharmaceuticals Inc. Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne
WO2015095840A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of cdk and erk inhibitors
WO2015106158A1 (en) * 2014-01-09 2015-07-16 Intra-Cellular Therapies, Inc. Organic compounds
ES2818110T3 (es) 2014-02-28 2021-04-09 Merck Sharp & Dohme Tratamiento del cáncer con una combinación que comprende dinaciclib
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
WO2015181737A1 (en) 2014-05-28 2015-12-03 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
SG10201902206QA (en) 2014-06-05 2019-04-29 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
PT3218005T (pt) 2014-11-12 2023-04-11 Seagen Inc Compostos que interagem com glicano e métodos de uso
EP3699181B1 (en) 2014-11-16 2023-03-01 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
CN106146515B (zh) * 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
US10724102B2 (en) 2015-10-26 2020-07-28 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
JP6692423B2 (ja) 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
JP7066613B2 (ja) 2015-11-12 2022-05-13 シージェン インコーポレイテッド グリカン相互作用化合物および使用方法
MX2018006250A (es) 2015-11-18 2018-09-05 Genzyme Corp Biomarcador de enfermedad poliquistica renal y usos del mismo.
AU2017217813B2 (en) 2016-02-12 2023-08-03 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
SG11201808559PA (en) 2016-04-04 2018-10-30 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
EP4104837A3 (en) 2016-04-15 2023-04-26 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
ES2886587T3 (es) 2016-04-15 2021-12-20 Cancer Research Tech Ltd Compuestos heterocíclicos como inhibidores de la quinasa RET
FI3800189T3 (fi) 2016-05-18 2023-07-31 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin valmistaminen
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN108017641B (zh) * 2016-11-02 2021-01-05 深圳铂立健医药有限公司 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
PL3579874T3 (pl) * 2017-02-10 2022-02-28 Novartis Ag 1-(4-amino-5-bromo-6-(1 h-pirazol-1-ilo)pirymidyn-2-ylo)-1 h-pirazol-4-ol i jego zastosowanie w leczeniu nowotworu złośliwego
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
MY205416A (en) 2017-07-28 2024-10-21 Takeda Pharmaceuticals Co Tyk2 inhibitors and uses thereof
IL277770B2 (en) 2018-04-11 2024-01-01 Qurient Co Ltd Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
ES2938751T3 (es) 2018-09-10 2023-04-14 Lilly Co Eli Derivados de pirazol[1,5-a]pirimidina-3-carboxamida útiles en el tratamiento de la psoriasis y el lupus eritematoso sistémico
CN113271940A (zh) 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
SG11202104229WA (en) 2018-10-30 2021-05-28 Kronos Bio Inc Compounds, compositions, and methods for modulating cdk9 activity
TWI800696B (zh) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
SG11202110523XA (en) 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
TWI882032B (zh) 2019-11-08 2025-05-01 美商凡帝克斯生物科學公司 Tyk2假激酶配位體
AR121251A1 (es) 2020-02-12 2022-05-04 Lilly Co Eli Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
CN116262752A (zh) * 2021-12-15 2023-06-16 上海壹迪生物技术有限公司 吡唑并嘧啶类化合物及其用途
CN119707984A (zh) * 2023-09-28 2025-03-28 中国科学院上海药物研究所 吡唑并三嗪及吡唑并嘧啶衍生物、其制备方法、药物组合物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US619131A (en) * 1899-02-07 Chester l
BE792533A (fr) * 1971-12-09 1973-06-08 Int Chem & Nuclear Corp Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
JPS6157587A (ja) * 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
CA2107479C (en) 1991-04-22 1997-12-16 Makoto Inoue Pyrazolo[1,5-a]pyrimidine derivatives and anti-inflammatory agent containing the same
JP2862374B2 (ja) * 1992-12-17 1999-03-03 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニスト活性を有するピラゾール及びピラゾロピリミジン
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
JP3710502B2 (ja) * 1993-10-21 2005-10-26 塩野義製薬株式会社 三環性化合物
DE69523864T2 (de) 1994-06-21 2002-06-13 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a] PYRIMIDIN-DERIVATE
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
FR2750048B1 (fr) * 1996-06-21 1998-08-14 Oreal Compositions de teinture des fibres keratiniques contenant des derives pyrazolo-(1, 5-a)-pyrimidine, procede de teinture, nouveaux derives pyrazolo-(1, 5-a)-pyrimidine et leur procede de preparation
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
DE69736711T2 (de) * 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
CA2314355A1 (en) 1997-12-13 1999-06-24 Bristol-Myers Squibb Company Use of pyrazolo ¢3,4-b! pyridine as cyclin dependent kinase inhibitors
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
FR2805160B1 (fr) * 2000-02-23 2002-04-05 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture
NZ525016A (en) 2000-09-15 2004-10-29 Vertex Pharma Isoxazoles and their use as inhibitors of ERK
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
WO2002050079A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
CN100343255C (zh) 2002-04-23 2007-10-17 盐野义制药株式会社 吡唑并[1,5－a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂
DE10223917A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Pyrazolopyrimidine
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2497440C (en) * 2002-09-04 2011-03-22 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7078525B2 (en) * 2002-09-04 2006-07-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
BRPI0407834A (pt) * 2003-02-28 2006-02-14 Teijin Pharma Ltd composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
JP2004277337A (ja) * 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
WO2005035516A1 (ja) * 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. 新規縮合複素環化合物およびその用途

Also Published As

Publication number Publication date
US20070054925A1 (en) 2007-03-08
NO337520B1 (no) 2016-05-02
ES2359410T3 (es) 2011-05-23
JP2010215675A (ja) 2010-09-30
JP2007522220A (ja) 2007-08-09
ZA200606573B (en) 2009-10-28
HRP20110245T1 (hr) 2011-04-30
CA2555345C (en) 2010-01-26
BRPI0507644B1 (pt) 2021-01-26
EP1720882A2 (en) 2006-11-15
BRPI0507644A (pt) 2007-04-17
NZ590480A (en) 2012-05-25
BRPI0507644B8 (pt) 2021-05-25
CY1112400T1 (el) 2015-12-09
DK1720882T3 (da) 2011-04-11
NO20064046L (no) 2006-11-10
KR20060127130A (ko) 2006-12-11
AU2005212409B2 (en) 2011-12-01
HK1090926A1 (en) 2007-01-05
KR101196498B1 (ko) 2012-11-01
SI1720882T1 (sl) 2011-05-31
RU2414472C2 (ru) 2011-03-20
TWI393566B (zh) 2013-04-21
CA2555345A1 (en) 2005-08-25
CN1946725A (zh) 2007-04-11
AR047543A1 (es) 2006-01-25
US20040209878A1 (en) 2004-10-21
PL1720882T3 (pl) 2011-08-31
WO2005077954A3 (en) 2005-10-13
IL177283A (en) 2015-10-29
AU2005212409A1 (en) 2005-08-25
PE20050774A1 (es) 2005-10-31
RU2006132288A (ru) 2008-03-20
JP4845743B2 (ja) 2011-12-28
US7119200B2 (en) 2006-10-10
AU2005212409C1 (en) 2012-07-19
CN1946725B (zh) 2011-02-23
WO2005077954A2 (en) 2005-08-25
RU2414472C9 (ru) 2011-11-20
MY149044A (en) 2013-07-15
EP1720882B1 (en) 2011-01-05
DE602005025733D1 (de) 2011-02-17
IL177283A0 (en) 2006-12-10
TW200528112A (en) 2005-09-01

Similar Documents

Publication Publication Date Title
ATE494287T1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
SMP200800022B (it) Benzimidazoli sostituiti come inibitori delle chinasi
DE602007008529D1 (de) Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
EP1951684A4 (en) BIARYLMETAPYRIMIDINKINASEINHIBITOREN
ATE452635T1 (de) Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ATE512972T1 (de) Pyrrolopyrazole als wirksame kinaseinhibitoren
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
ATE412652T1 (de) Triazolopyridinylsulfanylderivate als inhibitoren der p38-map-kinase
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
EP1893607A4 (en) CHECKPOINT KINASE INHIBITORS
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
ATE428708T1 (de) Neue phthalazinonderivate als aurora-a- kinaseinhibitoren
ATE493403T1 (de) Kinaseinhibitoren
DK1937650T3 (da) Heterocykliske forbindelser
NO20070299L (no) Novel heterocyclic compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1720882

Country of ref document: EP